Mobilizing Immunotherapy for Type 1 Diabetes: On the Horizon

[Northerner]

Type 1 diabetes mellitus (T1DM) is autoimmune in nature, and generally occurs when the body destroys all or part of its own roughly 1 billion β cells and cannot regenerate these critical endocrine components. Various mechanisms are involved in β-cell destruction. Researchers have turned their attention to immunotherapies, postulating that targeting the immune system might restore β-cell function. It appears that combination therapies may be needed since clinical trial results have not met expectations based on animal studies. A review article published ahead of print in Nature Reviews in Endocrinology speaks to this issue and summarizes current evidence about combination immunotherapies in T1DM.

http://www.hcplive.com/news/Mobilizing-Immunotherapy-for-Type-1-Diabetes-On-the-Horizon